475 related articles for article (PubMed ID: 33187130)
1. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis.
Jia J; Che L; Cigliano A; Wang X; Peitta G; Tao J; Zhong S; Ribback S; Evert M; Chen X; Calvisi DF
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187130
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.
Li L; Pilo GM; Li X; Cigliano A; Latte G; Che L; Joseph C; Mela M; Wang C; Jiang L; Ribback S; Simile MM; Pascale RM; Dombrowski F; Evert M; Semenkovich CF; Chen X; Calvisi DF
J Hepatol; 2016 Feb; 64(2):333-341. PubMed ID: 26476289
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
Che L; Chi W; Qiao Y; Zhang J; Song X; Liu Y; Li L; Jia J; Pilo MG; Wang J; Cigliano A; Ma Z; Kuang W; Tang Z; Zhang Z; Shui G; Ribback S; Dombrowski F; Evert M; Pascale RM; Cossu C; Pes GM; Osborne TF; Calvisi DF; Chen X; Chen L
Gut; 2020 Jan; 69(1):177-186. PubMed ID: 30954949
[TBL] [Abstract][Full Text] [Related]
4. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.
Liu P; Ge M; Hu J; Li X; Che L; Sun K; Cheng L; Huang Y; Pilo MG; Cigliano A; Pes GM; Pascale RM; Brozzetti S; Vidili G; Porcu A; Cossu A; Palmieri G; Sini MC; Ribback S; Dombrowski F; Tao J; Calvisi DF; Chen L; Chen X
Hepatology; 2017 Jul; 66(1):167-181. PubMed ID: 28370287
[TBL] [Abstract][Full Text] [Related]
5. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.
Hu J; Che L; Li L; Pilo MG; Cigliano A; Ribback S; Li X; Latte G; Mela M; Evert M; Dombrowski F; Zheng G; Chen X; Calvisi DF
Sci Rep; 2016 Feb; 6():20484. PubMed ID: 26857837
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of fatty acid synthase (FASN) affects the proliferation and apoptosis of HepG2 hepatoma carcinoma cells via the β-catenin/C-myc signaling pathway.
Zhang W; Huang J; Tang Y; Yang Y; Hu H
Ann Hepatol; 2020; 19(4):411-416. PubMed ID: 32536483
[TBL] [Abstract][Full Text] [Related]
7. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
[TBL] [Abstract][Full Text] [Related]
8. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.
Che L; Pilo MG; Cigliano A; Latte G; Simile MM; Ribback S; Dombrowski F; Evert M; Chen X; Calvisi DF
Cell Cycle; 2017 Mar; 16(6):499-507. PubMed ID: 28118080
[TBL] [Abstract][Full Text] [Related]
9. Osthole delays hepatocarcinogenesis in mice by suppressing AKT/FASN axis and ERK phosphorylation.
Mo Y; Wu Y; Li X; Rao H; Tian X; Wu D; Qiu Z; Zheng G; Hu J
Eur J Pharmacol; 2020 Jan; 867():172788. PubMed ID: 31712058
[TBL] [Abstract][Full Text] [Related]
10. The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans.
Xu Z; Xu M; Liu P; Zhang S; Shang R; Qiao Y; Che L; Ribback S; Cigliano A; Evert K; Pascale RM; Dombrowski F; Evert M; Chen X; Calvisi DF; Chen X
Hepatology; 2019 Nov; 70(5):1600-1613. PubMed ID: 31062368
[TBL] [Abstract][Full Text] [Related]
11. Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells.
Cao D; Song X; Che L; Li X; Pilo MG; Vidili G; Porcu A; Solinas A; Cigliano A; Pes GM; Ribback S; Dombrowski F; Chen X; Li L; Calvisi DF
Liver Int; 2017 Jan; 37(1):80-89. PubMed ID: 27264722
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Wang H; Zhou Y; Xu H; Wang X; Zhang Y; Shang R; O'Farrell M; Roessler S; Sticht C; Stahl A; Evert M; Calvisi DF; Zeng Y; Chen X
Hepatology; 2022 Oct; 76(4):951-966. PubMed ID: 35076948
[TBL] [Abstract][Full Text] [Related]
13. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
Wang H; Song X; Liao H; Wang P; Zhang Y; Che L; Zhang J; Zhou Y; Cigliano A; Ament C; Superville D; Ribback S; Reeves M; Pes GM; Liang B; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
Hepatology; 2021 Jul; 74(1):248-263. PubMed ID: 33368437
[TBL] [Abstract][Full Text] [Related]
15. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway.
Xia S; Ma J; Bai X; Zhang H; Cheng S; Zhang M; Zhang L; Du M; Wang Y; Li H; Rong R; Shi F; Yang Q; Leng J
Oncol Rep; 2014 Oct; 32(4):1521-30. PubMed ID: 25109834
[TBL] [Abstract][Full Text] [Related]
17. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.
Li L; Che L; Tharp KM; Park HM; Pilo MG; Cao D; Cigliano A; Latte G; Xu Z; Ribback S; Dombrowski F; Evert M; Gores GJ; Stahl A; Calvisi DF; Chen X
Hepatology; 2016 Jun; 63(6):1900-13. PubMed ID: 26910791
[TBL] [Abstract][Full Text] [Related]
18. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
Luo Y; Gao Y; Liu W; Yang Y; Jiang J; Wang Y; Tang W; Yang S; Sun L; Cai J; Guo X; Takahashi S; Krausz KW; Qu A; Chen L; Xie C; Gonzalez FJ
Hepatology; 2021 Oct; 74(4):1932-1951. PubMed ID: 33896016
[TBL] [Abstract][Full Text] [Related]
19. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1.
Shi W; Feng L; Dong S; Ning Z; Hua Y; Liu L; Chen Z; Meng Z
Cell Commun Signal; 2020 Jun; 18(1):100. PubMed ID: 32576198
[TBL] [Abstract][Full Text] [Related]
20. ZHX2 inhibits SREBP1c-mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p.
Yu X; Lin Q; Wu Z; Zhang Y; Wang T; Zhao S; Song X; Chen C; Wang Z; Xu L; Li C; Gao L; Liang X; Yue X; Ma C
J Pathol; 2020 Dec; 252(4):358-370. PubMed ID: 32770671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]